{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-043238","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.943505+00:00","generated_at":"2026-06-01T23:37:36.066415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Allarity Q1 net loss $3.8M; Phase 2 stenoparib benefit, equity $15M, Nasdaq compliance","bullets":["Phase 2 stenoparib trial concluded early due to clear clinical benefits: tumor shrinkage and long-term disease stability in ovarian cancer; preparing follow-on trial with FDA intent.","Cash balance $14M, stockholders' equity $15M, exceeding Nasdaq $2.5M minimum; seeking formal compliance confirmation.","Net loss $3.8M for Q1 2024 vs $3.4M Q1 2023; R&D expenses $2.2M (+$0.7M YoY), G&A $2.1M (flat).","Regained Nasdaq bid price compliance after reverse stock split; capital structure simplified: all variable-priced warrants exercised, Series A Preferred converted.","Withdrew Form S-1 registration; focus solely on stenoparib, deprioritizing IXEMPRA and dovitinib."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-043238","json":"https://secwatch.observer/filing/0001213900-24-043238.json","markdown":"https://secwatch.observer/filing/0001213900-24-043238.md","text":"https://secwatch.observer/filing/0001213900-24-043238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024043238/0001213900-24-043238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024043238/ea0206157-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:37:36.066415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0302d1362fb97d275e607135a96b6a87611bbbb","claim":"Allarity Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income -$3.8 million.","evidence_excerpt":"Net loss was $3.8 million for the quarter ended March 31, 2024, compared to $3.4 million for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024043238/0001213900-24-043238-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"-$3.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}